Breaking Age Barriers: The Benefits of CAR T-Cell Therapies in Treating Large B-Cell Lymphoma in Older Patients
The management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in older patients is challenging due to increased morbidity, toxicity and reduced effectiveness of therapy in this vulnerable and difficult-to-treat population. Chimeric antigen receptor (CAR) T-cell therapies have become a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2023.18.132 |